RVMD — Revolution Medicines, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1628171 ·
Last close
$205.26
Market Cap
$43.99B
52W High
$208.76
52W Low
$141.00
ADV30
1,974,329
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -505,132,000 | -644,371,000 | 4,323,270,000 | 815,435,000 | 1,717,032,000 |
| Mar 2026 | 0 | — | -445,222,000 | -453,816,000 | 2,253,737,000 | 440,939,000 | 753,820,000 |
| Dec 2025 | 0 | — | -361,626,000 | -364,892,000 | 2,354,508,000 | 383,745,000 | 723,211,000 |
| Sep 2025 | 0 | — | -315,269,000 | -305,206,000 | 2,251,920,000 | 217,442,000 | 655,016,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,577,198,000
Investing CF
$-1,213,709,000
Financing CF
$3,262,040,000
CapEx
$-10,636,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.82
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,967,289,000
Inventory
—
Receivables
$0
ST Investments
$3,122,534,000
EBIT TTM
$-1,708,943,000
Pretax Income TTM
$-1,768,285,000
Interest Exp TTM
$59,342,000
Analysts
21
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,182,369,000 | -1,131,301,000 | 2,354,508,000 | 723,211,000 | — | -897,741,000 |
| Dec 2024 | 0 | -689,524,000 | -600,093,000 | 2,558,301,000 | 293,097,000 | — | -557,436,000 |
| Dec 2023 | 11,580,000 | -487,185,000 | -436,367,000 | 2,061,705,000 | 235,511,000 | — | -350,572,000 |
| Dec 2022 | 35,380,000 | -258,279,000 | -248,705,000 | 811,930,000 | 126,742,000 | — | -224,401,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-6.60
Max Pain — expiry 2026-08-21
max pain strike: $175.00 · spot: $202.00 · call oi: 4,096 · put oi: 8,001
Expected Move to 2026-08-21:
±$10.45
(5.17%) —
implied range
$191.55 –
$212.45
· ATM straddle on $200.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARGX | ARGENX SE | $54.80B | $876.00 | — |
| BIIB | BIOGEN INC. | $30.86B | $208.87 | — |
| MRNA | Moderna, Inc. | $25.42B | $63.67 | — |
| BNTX | BioNTech SE | $23.30B | $92.74 | — |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.91B | $156.49 | — |
News headlines (Yahoo Finance, 1h cache)
Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript
2026-08-12 20:59 · Yahoo
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target
2026-08-12 12:50 · Yahoo
Revolution Medicines (RVMD) Stock Looks Rich On Fresh RAS Drug Demand
2026-08-12 09:11 · Yahoo
Revolution Medicines (RVMD) Is Up 6.2% After BeOne-Funded Phase 3 RAS(ON) Deal - Has The Bull Case Changed?
2026-08-12 06:14 · Yahoo
Revolution Medicines (RVMD) Looks Fairly Valued As BeOne Deal Expands Its Asia Reach
2026-08-12 02:35 · Yahoo
BeOne and Revolution Medicines partner for oncology therapies
2026-08-11 10:45 · Yahoo
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
2026-08-07 10:02 · Yahoo
Revolution Medicines Q2 Earnings Call Highlights
2026-08-06 04:03 · Yahoo
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
2026-08-05 20:02 · Yahoo
Billionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?
2026-08-03 08:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.